57183-08-1

Usage

Uses

Used in Organic Synthesis:
(5-(benzyloxy)-4,6-dimethylpyridin-3-yl)methanol is used as a building block or intermediate for the preparation of various pharmaceutical compounds. Its unique molecular structure, including the pyridine ring and benzene ring, allows it to participate in a variety of chemical reactions, making it a valuable component in the synthesis of complex molecules.
Used in Medicinal Chemistry:
(5-(benzyloxy)-4,6-dimethylpyridin-3-yl)methanol is used as a key intermediate in the development of pharmaceutical compounds. Its chemical properties, such as the presence of the pyridine ring, contribute to its usefulness in medicinal applications, enabling the creation of new drugs with potential therapeutic benefits.
Used in Chemical Research:
(5-(benzyloxy)-4,6-dimethylpyridin-3-yl)methanol is also used in chemical research to study the properties and reactivity of complex organic molecules. Its unique structure allows researchers to explore new reaction pathways and develop innovative synthetic methods for the preparation of novel compounds.

Upstream product

• 148-51-6 3-hydroxy-5-hydroxymethyl-2,4-dimethylpyridinium chloride 
• 100-44-7 benzyl chloride 
• 58-56-0 pyridoxal hydrochloride 
• 3204-68-0 benzyldimethylphenylammonium chloride 

Downstream Products

• 57183-26-3 5-benzyloxy-4,6-dimethylnicotinaldehyde 
• 883-84-1 4-Deoxypyridoxin-5'-phosphat 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOSITION CONTAINING, AS ACTIVE INGREDIENT, 7-AZAINDOLIN-2-ONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

The present invention relates to a 7-azaindolin-2-one derivative or a pharmaceutically acceptable salt thereof, and the 7-azaindolin-2-one derivative or the pharmaceutically acceptable salt thereof can be favorably used as a medicinal material for inhibiting cancer growth and cancer metastasis.

5-Hydroxy-7-azaindolin-2-one, a novel hybrid of pyridinol and sunitinib: Design, synthesis and cytotoxicity against cancer cells

Angiogenesis plays important roles in tumor growth and metastasis. Sunitinib (Sutent) is an antitumor agent targeting receptor tyrosine kinases which are involved in angiogenesis as well as cancer cell growth and survival. Using the pyridin-3-ol scaffold, which was previously reported as an excellent antioxidant and antiangiogenic platform, we have synthesized sunitinib mimics 6 by hybridizing bicyclic pyridinol 4 as a key scaffold and pyrrole-2-carbaldehydes 7 as side chains. Cytotoxicity assays showed that compounds 6 have comparable to better anticancer activity than sunitinib against five different cancer cell lines. In addition, compounds 6 showed even lower levels of cytotoxicity against normal cells, resulting in up to 26-fold better safety windows, than sunitinib. Signaling pathway-associated transcription factor reporter assay and western blot analyses revealed that apoptosis induction in MDA-MB-231 human breast cancer cells by 6F is mainly mediated through the p53 increase and down-regulation of phospho-signal transducer and activator of transcription 3 (STAT3) and its target gene products, cyclin D, Bcl-2, and survivin. The data strongly suggest that our hybrid compounds can provide a novel anticancer scaffold with improved and safer cytotoxicity profiles than sunitinib.

Pyridoxine-derived bicyclic amido-, ureido-, and carbamato-pyridinols: Synthesis and antiangiogenic activities

We recently developed an efficient and practical synthesis for a novel series of pyridoxine-derived 6-amido-2,4,5-trimethylpyridin-3-ols and found that this novel scaffold has outstanding activity to inhibit angiogenesis measured by the quantitative chick embryo chorioallantoic membrane (CAM) assay. As an effort to extend the scope of the amidopyridinol scaffold, we here report the synthesis and antiangiogenic activities of a series of bicyclic versions of the amidopyridinol including five- and six-membered cyclic amide-, cyclic urea-, and cyclic carbamate-fused pyridinols. The six membered bicyclic derivatives were prepared by the reported procedures, and the five-membered ring-fused ones were synthesized by new synthetic methods developed in this study. CAM assays showed that both six- and five-membered lactam-fused pyridinols have activities comparable to sunitinib malate, the positive control, in inhibition of vascular endothelial growth factor-induced angiogenesis. On the other hand, the urea and the carbamate derivatives showed modest to moderate antiangiogenic activities. In summary, some bicyclic aminopyridinols can provide a good platform for structural exploitation in future medicinal chemistry work.

Novel heteroaryl phosphonates as cardioprotective agents

The invention teaches compound of general formula: Wherein: R1 is selected from H and CH3, and R2 is selected from H and OH, or R1 and R2 together form an optionally substituted phenyl ring which is fused to the pyridine ring; and R3 is selected from H, CH3, CH2OH and R4 is selected from H, CH3, CH2OH, R5 is selected from H, phenyl, halogen-substituted phenyl and Wherein R6 and R7 are each independently selected from H, Na+, K+, alkyl and optionally substituted aryl, and X and Y are each independently selected from H, OH and F, or at least one of X and Y is an heteroatom and together with R3 forms a bridge with the proviso that R4 is and N-oxides thereof, and biologically acceptable salts thereof, related compounds, related pharmaceutical compositions, and methods for treating various disorders using such compositions.